E125: Kiyatec Cracks the Code for Predicting Response to Chemotherapy

Venture In The South

E125: Kiyatec is a Cancer Diagnostics Startup focused on solving the problem of selecting the best chemotherapy for each individual cancer patient's specific cancer. The standard of care today is essentially trial and error following a menu of consensus empiric chemotherapy choices, then trying the most likely effective drug first and measuring response. Kiyatec's solution, 3-D Predict, uses a proprietary 3-D cell culture technique that grows cancer cells in the lab, directly from a tumor biopsy and tests those cells against all the consensus empiric chemotherapy choices. This test identifies the drug that is most effective at killing that specific tumor with a 98% positive predictive value within 7 days. Compared to cancer cell genomics, which identifies genetic markers associated with response to treatment, 3-D Predict actually measures the response. This is a game changer in Oncology because it eliminates educated guessing, avoiding the common scenario of taking a drug that doesn't work and experiencing side effects for no benefit. Kiyatec has published multiple peer reviewed studies proving the accuracy of 3-D Predict in Glioblastoma and Ovarian cancer while preparing documentation to support accuracy for the really big cancers like Lung, Breast and Prostate. David interviews CEO Eric Perreault for the Kiyatec story and the 4 key milestones he aims to achieve in 2024 to support a $15-20M growth equity raise in 2025. (recorded 6/28/24)

Follow David on LinkedIn or reach out to David on Twitter/X @DGRollingSouth for comments.
Follow Paul on LinkedIn or reach out to Paul on Twitter/X @PalmettoAngel
We invite your feedback and suggestions at www.ventureinthesouth.com or email [e-mail]. Learn more about RollingSouth at rollingsouth.vc or email [e-mail].